PAI
ITCI

Palo Alto Investors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Palo Alto Investors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-37,400
Closed -$960K – 44
2020
Q2 		$960K Hold
37,400
– – 0.06% 34
2020
Q1 		$575K Hold
37,400
– – 0.05% 31
2019
Q4 		$1.28M Buy
+37,400
New +$449K 0.07% 30

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Palo Alto Investors's ITCI Position: Q3 2020 in Review

Palo Alto Investors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2020, closing a stake of 37,400 shares — an estimated $960K sold.

Palo Alto Investors first reported a position in ITCI in Q4 2019 and held it in 3 quarters. The position peaked at $1.28M in Q4 2019. 176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

  • Palo Alto Investors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2020 after selling out during the quarter.
  • Palo Alto Investors sold 37,400 Intra-Cellular Therapies Inc. shares in Q3 2020, an estimated $960K.
  • Palo Alto Investors first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 3 quarters.
  • Palo Alto Investors's Intra-Cellular Therapies Inc. position peaked at $1.28M in Q4 2019.
  • 176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on Palo Alto Investors's 13F filing for Q3 2020, filed 16 Nov 2020.